EVERSANA Named by Precigen for U.S. Commercialization of PAPZIMEOS [Yahoo! Finance]
Precigen, Inc. (PGEN)
Last precigen, inc. earnings: 3/2 04:05 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
the life sciences industry, has been named by Precigen, Inc. for commercialization of PAPZIMEOS™ (zopapogene imadenovec-drba), approved by the U.S. Food and Drug Administration on August 14, 2025. EVERSANA logo (PRNewsfoto/EVERSANA) Since partnering in late 2024, Precigen has leveraged EVERSANA's full-scale commercialization operation for pre-approval planning and has activated immediate post-approval launch services, including areas covered by market access, field deployment, medical affairs, and marketing services. "Our model is built to overcome the complexity of rare disease therapy launches," said Greg Skalicky, President, EVERSANA. "We will immediately deploy our ever-evolving capabilities to accelerate access for patients across the United States." To learn more about EVERSANA's commercialization services, visit eversana.com About EVERSANA EVERSANA ® is a leading independent provider of global services to the life sciences industry. The company's integrated solutions
Show less
Read more
Impact Snapshot
Event Time:
PGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PGEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PGEN alerts
High impacting Precigen, Inc. news events
Weekly update
A roundup of the hottest topics
PGEN
News
- Precigen Is Still A Buy After The Papzimeos Rally [Seeking Alpha]Seeking Alpha
- Vaxart, Precigen among biotech gainers after Q3 results [Seeking Alpha]Seeking Alpha
- Precigen (NASDAQ:PGEN) had its price target raised by analysts at HC Wainwright from $8.50 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Precigen Inc (PGEN) Q3 2025 Earnings Call Highlights: FDA Approval and U.S. ... [Yahoo! Finance]Yahoo! Finance
- Precigen to Announce Third Quarter 2025 Financial Results and Provide Business Updates on November 13 [Yahoo! Finance]Yahoo! Finance
PGEN
Earnings
- 11/13/25 - Miss
PGEN
Sec Filings
- 11/21/25 - Form SCHEDULE
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- PGEN's page on the SEC website